CO5560547A2 - Metodos para la preparacion de compuestos de pirrolotriazina utiles como inhibidores de cinasa - Google Patents
Metodos para la preparacion de compuestos de pirrolotriazina utiles como inhibidores de cinasaInfo
- Publication number
- CO5560547A2 CO5560547A2 CO05043491A CO05043491A CO5560547A2 CO 5560547 A2 CO5560547 A2 CO 5560547A2 CO 05043491 A CO05043491 A CO 05043491A CO 05043491 A CO05043491 A CO 05043491A CO 5560547 A2 CO5560547 A2 CO 5560547A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- compounds
- sub
- pirrolotriazine
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/50—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
1.- Un método de formar un pirrol aminado que comprende: hacer reaccionar un compuesto de la Fórmula IV en donde R1 se selecciona de H, alquilo, aralquilo, OR1, OC(O)R1, OC(O)OR1, OC(O)NR1AND#39R1", OS(O)2R1"AND#39, y OS(O)2NR1AND#39R1", en donde los grupos R1AND#39 y R1" pueden ser cada uno en forma independiente H, alquilo, arilo, aralquilo, heterociclo, o grupos cicloalquilo, o pueden tomarse conjuntamente para formar un grupo cicloalquilo, arilo, o heterocíclico, cualquiera de los cuales puede sustituirse de manera opcional, y el grupo R1AND#39" se define como un alquilo, arilo, aralquilo, heterociclo, o cicloalquilo; -SCH3, -OC(=O)R21, -S(=O)R22, -SO2R22, -SO2NR24R25, -CO2R21, -C(=O)NR24R25, -NH2, -NR24R25, NR21SO2NR24R25, -NR21SO2R22, -NR24C(=O)R25, -NR24CO2R25, NR21C(=O)NR24R25, halógeno, nitro, o ciano;A se selecciona de R2X o E, donde X se selecciona de -O-, -OC(=O)-, -S-, -S(=O)-, -SO2- -C(=O)-, -CO2-, -NR10-, -NR10C(=O)-, NR10C(=O)NR11-, -NR10CO2-, -NR10SO2-, -NR10SO2NR11-, SO2NR10-, -C(=O)NR10-, halógeno, nitro, y ciano, o X está ausente; y E es un grupo de retiro de electrones; o R1, tomado conjuntamente con A, puede formar un anillo heterocíclico o aromático, saturado o insaturado, sustituido de manera opcional; R2 se selecciona de: (i) hidrógeno, con la condición de que R2 no es hidrógeno si X es -S(=O)-, -SO2-, -NR10CO2-, o -NR10SO2-; (ii) alquilo, alquenilo, y alquinilo sustituido de manera opcional con hasta cuatro R26; (iii) arilo y heteroarilo sustituido de manera opcional con hasta tres R27; (iv) heterocicIo y cicIoalquilo sustituido de manera opcional con ceto (=O), hasta tres R27, y/o con un puente carbono-carbono de 3 a 4 átomos de carbono; o (v) -C(O)Rb donde Rb es H, OH, alquilo, aralquilo, halo, ORbAND#39, OC(O)RbAND#39, OC(O)ORbAND#39, OC(O)NRbRbAND#39, OS(O)RbAND#39, OS(O)NRbRbAND#39, y Rb y RbAND#39 se seleccionan cada uno independientemente de H, alquilo, aralquilo, heterocicIo o cicIoalquilo, o Rb y RbAND#39 conjuntamente forman un grupo cicIoalquilo, arilo o heterocicIo; sin embargo, R2 está ausente si X es halógeno, nitro o ciano; ...
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/289,010 US6867300B2 (en) | 2000-11-17 | 2002-11-06 | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5560547A2 true CO5560547A2 (es) | 2005-09-30 |
Family
ID=32312096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO05043491A CO5560547A2 (es) | 2002-11-06 | 2005-05-05 | Metodos para la preparacion de compuestos de pirrolotriazina utiles como inhibidores de cinasa |
Country Status (16)
Country | Link |
---|---|
US (2) | US6867300B2 (es) |
EP (1) | EP1562949B1 (es) |
JP (1) | JP4662775B2 (es) |
KR (1) | KR20050084961A (es) |
CN (1) | CN100360532C (es) |
AT (1) | ATE453645T1 (es) |
AU (1) | AU2003287514A1 (es) |
BR (1) | BR0316056A (es) |
CA (1) | CA2505365A1 (es) |
CO (1) | CO5560547A2 (es) |
DE (1) | DE60330800D1 (es) |
ES (1) | ES2337571T3 (es) |
MX (1) | MXPA05004748A (es) |
PL (1) | PL377112A1 (es) |
TW (1) | TWI290555B (es) |
WO (1) | WO2004043912A2 (es) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6982265B1 (en) * | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
US6670357B2 (en) * | 2000-11-17 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
US6867300B2 (en) * | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
TW200300350A (en) * | 2001-11-14 | 2003-06-01 | Bristol Myers Squibb Co | C-5 modified indazolylpyrrolotriazines |
JP2005529890A (ja) | 2002-04-23 | 2005-10-06 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤として有用なアリールケトンピロロトリアジン化合物 |
US7388009B2 (en) | 2002-04-23 | 2008-06-17 | Bristol-Myers Squibb Company | Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors |
RS92004A (en) * | 2002-04-23 | 2006-12-15 | Bristol-Myers Squibb Company | Pyrrolo-triazine aniline compounds useful as kinase inhibitors |
TW200401638A (en) * | 2002-06-20 | 2004-02-01 | Bristol Myers Squibb Co | Heterocyclic inhibitors of kinases |
TWI329112B (en) * | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
TW200420565A (en) | 2002-12-13 | 2004-10-16 | Bristol Myers Squibb Co | C-6 modified indazolylpyrrolotriazines |
EP1590335A4 (en) | 2003-02-05 | 2006-03-08 | Bristol Myers Squibb Co | PROCESS FOR THE PRODUCTION OF PYRROLOTRIAZINKINASE INHIBITORS |
US20060014741A1 (en) * | 2003-12-12 | 2006-01-19 | Dimarco John D | Synthetic process, and crystalline forms of a pyrrolotriazine compound |
US7102001B2 (en) | 2003-12-12 | 2006-09-05 | Bristol-Myers Squibb Company | Process for preparing pyrrolotriazine |
US7064203B2 (en) | 2003-12-29 | 2006-06-20 | Bristol Myers Squibb Company | Di-substituted pyrrolotriazine compounds |
MY145634A (en) * | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
US7829720B2 (en) | 2004-05-04 | 2010-11-09 | Bristol-Myers Squibb Company | Process for preparing atazanavir bisulfate and novel forms |
TWI354569B (en) | 2004-05-28 | 2011-12-21 | Bristol Myers Squibb Co | Coated tablet formulation and method |
US7102002B2 (en) | 2004-06-16 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US7432373B2 (en) * | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
US7173031B2 (en) * | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US7439246B2 (en) * | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
US7253167B2 (en) * | 2004-06-30 | 2007-08-07 | Bristol-Myers Squibb Company | Tricyclic-heteroaryl compounds useful as kinase inhibitors |
TW200600513A (en) * | 2004-06-30 | 2006-01-01 | Bristol Myers Squibb Co | A method for preparing pyrrolotriazine compounds |
US7102003B2 (en) * | 2004-07-01 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
US7504521B2 (en) * | 2004-08-05 | 2009-03-17 | Bristol-Myers Squibb Co. | Methods for the preparation of pyrrolotriazine compounds |
PE20060421A1 (es) | 2004-08-12 | 2006-06-01 | Bristol Myers Squibb Co | Procedimiento para preparar un compuesto de pirrolotriazina anilina como inhibidores de cinasa |
US7713973B2 (en) * | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US7151176B2 (en) * | 2004-10-21 | 2006-12-19 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
US7514435B2 (en) * | 2005-11-18 | 2009-04-07 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US7348325B2 (en) * | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
PE20070855A1 (es) | 2005-12-02 | 2007-10-14 | Bayer Pharmaceuticals Corp | Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas |
JP5249776B2 (ja) | 2005-12-02 | 2013-07-31 | バイエル・ヘルスケア・エルエルシー | 過剰増殖性疾患および血管新生と関連する疾患を処置するために有用な置換された4−アミノ−ピロロトリアジン誘導体 |
US8063208B2 (en) | 2006-02-16 | 2011-11-22 | Bristol-Myers Squibb Company | Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol |
JP5693239B2 (ja) | 2008-01-23 | 2015-04-01 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 4−ピリジノン化合物および癌についてのその使用 |
TW201035100A (en) | 2008-12-19 | 2010-10-01 | Cephalon Inc | Pyrrolotriazines as ALK and JAK2 inhibitors |
WO2012031057A1 (en) | 2010-09-01 | 2012-03-08 | Bristol-Myers Squibb Company | Bms- 582949 for the treatment of resistant rheumatic disease |
CN102153558B (zh) * | 2011-02-23 | 2012-11-21 | 扬州永济医药新技术有限公司 | 多靶点抗肿瘤抑制剂2-氨吡咯-三嗪的衍生物及其合成方法 |
CN103450204B (zh) | 2012-05-31 | 2016-08-17 | 中国科学院上海药物研究所 | 吡咯[2,1-f][1,2,4]并三嗪类化合物,其制备方法及用途 |
US9724352B2 (en) | 2012-05-31 | 2017-08-08 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof |
CN104003990B (zh) * | 2013-02-21 | 2017-09-15 | 江苏先声药业有限公司 | 杂环胺类Hedgehog信号通路抑制剂 |
US9050345B2 (en) | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
CN104788460B (zh) * | 2015-03-27 | 2016-11-09 | 陕西师范大学 | 4-芳氨基吡咯并[2,1-f][1,2,4]三嗪衍生物的制备方法 |
US11760701B2 (en) | 2018-02-27 | 2023-09-19 | The Research Foundation For The State University Of New Yrok | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same |
CN108516977A (zh) * | 2018-07-10 | 2018-09-11 | 刘凤娟 | 一种用于治疗恶性肿瘤的map激酶抑制剂的合成方法 |
CN111234067B (zh) * | 2018-11-29 | 2021-08-03 | 中国石油化工股份有限公司 | 用于烯烃聚合的固体催化剂组分和催化剂及其应用 |
CN113372263B (zh) * | 2021-05-21 | 2022-04-19 | 温州医科大学 | 一种2-氯-3-胺基萘醌化合物的制备方法 |
CN113292503B (zh) * | 2021-05-22 | 2022-05-13 | 台州市第一人民医院 | 一种2-溴-3-胺基萘醌化合物的制备方法 |
CN116789674B (zh) * | 2022-08-24 | 2024-05-24 | 杭州高光制药有限公司 | Nlrp3炎性小体抑制剂 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4908056A (en) | 1986-04-25 | 1990-03-13 | E. I. Du Pont De Nemours And Company | Heterocyclic acyl sulfonamides |
DE59500788D1 (de) | 1994-05-03 | 1997-11-20 | Ciba Geigy Ag | Pyrrolopyrimidinderivate mit antiproliferativer Wirkung |
CA2163399A1 (en) | 1994-11-24 | 1996-05-25 | Katsuhiro Kawano | Triazine derivative, chymase activity inhibitor and nitric oxide production inhibitor |
IL118544A (en) | 1995-06-07 | 2001-08-08 | Smithkline Beecham Corp | History of imidazole, the process for their preparation and the pharmaceutical preparations containing them |
DK0778277T3 (da) | 1995-12-08 | 2003-10-27 | Pfizer | Substituerede heterocycliske derivater som CRF antagonister |
CZ216498A3 (cs) | 1996-01-11 | 1999-08-11 | Smithkline Beecham Corporation | Nové substituované imidazolové sloučeniny |
GB9604361D0 (en) | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
US20010007867A1 (en) | 1999-12-13 | 2001-07-12 | Yuhpyng L. Chen | Substituted 6,5-hetero-bicyclic derivatives |
AU735401B2 (en) | 1996-08-28 | 2001-07-05 | Pfizer Inc. | Substituted 6,5-hetero-bicyclic derivatives |
US6147080A (en) | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
US5945418A (en) | 1996-12-18 | 1999-08-31 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
US6087496A (en) | 1998-05-22 | 2000-07-11 | G. D. Searle & Co. | Substituted pyrazoles suitable as p38 kinase inhibitors |
RU2249591C2 (ru) | 1997-05-22 | 2005-04-10 | Дж.Д. Серл Энд Ко. | 3(5)-гетероарилзамещенные пиразолы в качестве ингибиторов киназы p38 |
WO1999001452A1 (en) | 1997-07-02 | 1999-01-14 | Smithkline Beecham Corporation | Novel cycloalkyl substituted imidazoles |
WO1999024033A1 (en) | 1997-11-12 | 1999-05-20 | Shionogi & Co., Ltd. | Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds |
US6130235A (en) | 1998-05-22 | 2000-10-10 | Scios Inc. | Compounds and methods to treat cardiac failure and other disorders |
US6410540B1 (en) | 1998-08-28 | 2002-06-25 | Scios, Inc. | Inhibitors of p38-αkinase |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
US6593333B1 (en) | 1998-10-01 | 2003-07-15 | Astrazeneca Ab | Substituted anilino-quinazoline (or quinoline) compounds and use thereof |
GB9906566D0 (en) | 1999-03-23 | 1999-05-19 | Zeneca Ltd | Chemical compounds |
DK1183033T3 (da) | 1999-05-21 | 2006-06-06 | Bristol Myers Squibb Co | Pyrrolotriazininhibitorer af kinaser |
WO2001014378A1 (fr) | 1999-08-23 | 2001-03-01 | Shionogi & Co., Ltd. | DERIVES DE PYRROLOTRIAZINE A ACTIVITES INHIBANT sPLA¿2? |
GB9924092D0 (en) | 1999-10-13 | 1999-12-15 | Zeneca Ltd | Pyrimidine derivatives |
IL139197A0 (en) | 1999-10-29 | 2001-11-25 | Pfizer Prod Inc | Use of corticotropin releasing factor antagonists and related compositions |
RU2264403C2 (ru) | 1999-11-10 | 2005-11-20 | Орто-Макнейл Фармасьютикал, Инк. | Замещенные 2-арил-3-(гетероарил) имидазо [1,2-а] пиримидины, содержащие их фармацевтические композиции и связанные с ними способы |
US20020065270A1 (en) | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
ATE449764T1 (de) | 1999-12-28 | 2009-12-15 | Pharmacopeia Inc | Cytokine, insbesondere tnf-alpha, hemmer |
US6906067B2 (en) | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
EP1149583A3 (en) | 2000-04-13 | 2001-11-14 | Pfizer Products Inc. | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues |
US6518269B1 (en) | 2000-07-28 | 2003-02-11 | University Of Arizona Foundation | Cancer treatment |
US6867300B2 (en) * | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
JP2004522713A (ja) | 2000-11-17 | 2004-07-29 | ブリストル−マイヤーズ スクイブ カンパニー | p38キナーゼ関連疾患の処置方法およびキナーゼインヒビターとして有用なピロロトリアジン化合物 |
US6670357B2 (en) | 2000-11-17 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
JP4510442B2 (ja) | 2001-06-26 | 2010-07-21 | ブリストル−マイヤーズ スクイブ カンパニー | TNF−α発現のN−ヘテロ環インヒビター |
TW200300350A (en) | 2001-11-14 | 2003-06-01 | Bristol Myers Squibb Co | C-5 modified indazolylpyrrolotriazines |
US7388009B2 (en) | 2002-04-23 | 2008-06-17 | Bristol-Myers Squibb Company | Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors |
RS92004A (en) | 2002-04-23 | 2006-12-15 | Bristol-Myers Squibb Company | Pyrrolo-triazine aniline compounds useful as kinase inhibitors |
JP2005529890A (ja) | 2002-04-23 | 2005-10-06 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤として有用なアリールケトンピロロトリアジン化合物 |
TW200407143A (en) | 2002-05-21 | 2004-05-16 | Bristol Myers Squibb Co | Pyrrolotriazinone compounds and their use to treat diseases |
TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
TWI272271B (en) | 2002-07-19 | 2007-02-01 | Bristol Myers Squibb Co | Process for preparing certain pyrrolotriazine compounds |
WO2004013145A1 (en) | 2002-08-02 | 2004-02-12 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
TW200420565A (en) | 2002-12-13 | 2004-10-16 | Bristol Myers Squibb Co | C-6 modified indazolylpyrrolotriazines |
EP1590335A4 (en) | 2003-02-05 | 2006-03-08 | Bristol Myers Squibb Co | PROCESS FOR THE PRODUCTION OF PYRROLOTRIAZINKINASE INHIBITORS |
US7419978B2 (en) | 2003-10-22 | 2008-09-02 | Bristol-Myers Squibb Company | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors |
US7102001B2 (en) | 2003-12-12 | 2006-09-05 | Bristol-Myers Squibb Company | Process for preparing pyrrolotriazine |
US7064203B2 (en) | 2003-12-29 | 2006-06-20 | Bristol Myers Squibb Company | Di-substituted pyrrolotriazine compounds |
MY145634A (en) | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
-
2002
- 2002-11-06 US US10/289,010 patent/US6867300B2/en not_active Expired - Fee Related
-
2003
- 2003-11-03 DE DE60330800T patent/DE60330800D1/de not_active Expired - Lifetime
- 2003-11-03 JP JP2004551735A patent/JP4662775B2/ja not_active Expired - Fee Related
- 2003-11-03 PL PL377112A patent/PL377112A1/pl not_active Application Discontinuation
- 2003-11-03 KR KR1020057008063A patent/KR20050084961A/ko not_active Application Discontinuation
- 2003-11-03 WO PCT/US2003/035220 patent/WO2004043912A2/en active Application Filing
- 2003-11-03 ES ES03781756T patent/ES2337571T3/es not_active Expired - Lifetime
- 2003-11-03 EP EP03781756A patent/EP1562949B1/en not_active Expired - Lifetime
- 2003-11-03 CA CA002505365A patent/CA2505365A1/en not_active Abandoned
- 2003-11-03 BR BR0316056-4A patent/BR0316056A/pt not_active IP Right Cessation
- 2003-11-03 CN CNB2003801082297A patent/CN100360532C/zh not_active Expired - Fee Related
- 2003-11-03 AT AT03781756T patent/ATE453645T1/de not_active IP Right Cessation
- 2003-11-03 AU AU2003287514A patent/AU2003287514A1/en not_active Abandoned
- 2003-11-03 MX MXPA05004748A patent/MXPA05004748A/es active IP Right Grant
- 2003-11-04 TW TW092130839A patent/TWI290555B/zh not_active IP Right Cessation
-
2004
- 2004-12-22 US US11/019,788 patent/US7211666B2/en not_active Expired - Fee Related
-
2005
- 2005-05-05 CO CO05043491A patent/CO5560547A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TWI290555B (en) | 2007-12-01 |
WO2004043912A3 (en) | 2004-07-01 |
PL377112A1 (pl) | 2006-01-23 |
ATE453645T1 (de) | 2010-01-15 |
KR20050084961A (ko) | 2005-08-29 |
CA2505365A1 (en) | 2004-05-27 |
BR0316056A (pt) | 2005-09-27 |
EP1562949A2 (en) | 2005-08-17 |
US20030186982A1 (en) | 2003-10-02 |
EP1562949A4 (en) | 2007-09-12 |
TW200413382A (en) | 2004-08-01 |
AU2003287514A1 (en) | 2004-06-03 |
CN100360532C (zh) | 2008-01-09 |
CN1735615A (zh) | 2006-02-15 |
DE60330800D1 (de) | 2010-02-11 |
ES2337571T3 (es) | 2010-04-27 |
JP2006514622A (ja) | 2006-05-11 |
EP1562949B1 (en) | 2009-12-30 |
WO2004043912A2 (en) | 2004-05-27 |
US20050107462A1 (en) | 2005-05-19 |
MXPA05004748A (es) | 2005-08-03 |
JP4662775B2 (ja) | 2011-03-30 |
US6867300B2 (en) | 2005-03-15 |
US7211666B2 (en) | 2007-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5560547A2 (es) | Metodos para la preparacion de compuestos de pirrolotriazina utiles como inhibidores de cinasa | |
EA200401378A1 (ru) | N-замещенные трициклические 3-аминопиразолы в качестве ингибиторов pdgf рецептора | |
EA200970149A1 (ru) | Производные n-(аминогетероарил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии | |
NO20081941L (no) | Pyrazol [1,5-alfa]pyrimidinylderivater nyttige som kortikotropin-frigivende faktor (CRF) reseptorantagonister | |
NO20075142L (no) | krystallformer av asenapinmaleat | |
EA200501009A1 (ru) | Замещённые пирролопиразольные производные в качестве ингибиторов киназы | |
EA200300248A1 (ru) | Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции | |
ATE437872T1 (de) | Proteinkinaseinhibitoren | |
ATE401066T1 (de) | Methoden zur behandlung der essstörungen | |
WO2007054770A3 (en) | Pyrazole derivatives and their medical use | |
CA2523261A1 (en) | Fused pyrimidine derivatives with crf activity | |
NO324228B1 (no) | 4-amino-5-cyano-2-anilino-pyrimidinderivater og deres anvendelse og fremgangsmate for fremstilling, samt farmasoytisk sammensetning | |
CY1111275T1 (el) | Κρυσταλλικη μορφη μιας ενωσης κινολινονης-καρβοξαμιδιου | |
IS8377A (is) | Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns | |
EA200600621A1 (ru) | Производные тетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств | |
EA200401455A1 (ru) | Производные бензоксазина в качестве модуляторов 5-htи их применение | |
WO2006124996A3 (en) | Inhibitors of polo-like kinase-1 | |
NO20070550L (no) | Fremgangsmate for fremstilling av pyrrolotriazinforbindelser | |
WO2006029210A3 (en) | Acyclic 1,3-diamines and uses therefor | |
ATE299878T1 (de) | Verfahren zur herstellung von azacycloalkanoylaminothiazolen | |
ITMI20020933A1 (it) | Procedimento per la sintesi di clopidogrel | |
AU3324201A (en) | Tosylproline analogs as thymidylate synthase inhibitors | |
SE0301371D0 (sv) | New Compounds | |
BRPI0620694A2 (pt) | composto, composição farmacêutica, processo para a preparação do composto, método para o tratamento de doenças inflamatórias mediado pela ativação de p38 map quinase e uso do composto | |
NO20042729L (no) | Heksasykliske forbindelser |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |